Droplet-based Microtumor Model to Assess Cell-ECM Interactions and Drug Resistance of Gastric Cancer Cells
Affiliations
Gastric cancer (GC) is a common aggressive malignant tumor with high incidence and mortality worldwide. GC is classified into intestinal and diffuse types according to the histo-morphological features. Because of distinctly different clinico-pathological features, new cancer therapy strategies and in vitro preclinical models for the two pathological variants of GC is necessary. Since extracellular matrix (ECM) influence the biological behavior of tumor cells, we hypothesized that GC might be more similarly modeled in 3D with matrix rather than in 2D. Herein, we developed a microfluidic-based a three-dimensional (3D) in vitro gastric cancer model, with subsequent drug resistance assay. AGS (intestinal type) and Hs746T (diffuse type) gastric cancer cell lines were encapsulated in collagen beads with high cellular viability. AGS exhibited an aggregation pattern with expansive growth, whereas Hs746T showed single-cell-level infiltration. Importantly, in microtumor models, epithelial-mesenchymal transition (EMT) and metastatic genes were upregulated, whereas E-cadherin was downregulated. Expression of ß-catenin was decreased in drug-resistant cells, and chemosensitivity toward the anticancer drug (5-FU) was observed in microtumors. These results suggest that in vitro microtumor models may represent a biologically relevant platform for studying gastric cancer cell biology and tumorigenesis, and for accelerating the development of novel therapeutic targets.
Tumor-microenvironment-on-a-chip: the construction and application.
Xu H, Wen J, Yang J, Zhou S, Li Y, Xu K Cell Commun Signal. 2024; 22(1):515.
PMID: 39438954 PMC: 11515741. DOI: 10.1186/s12964-024-01884-4.
IQGAP3 signalling mediates intratumoral functional heterogeneity to enhance malignant growth.
Shimura M, Matsuo J, Pang S, Jangphattananont N, Hussain A, Rahmat M Gut. 2024; 74(3):364-386.
PMID: 39438124 PMC: 11874294. DOI: 10.1136/gutjnl-2023-330390.
Preclinical evaluation of fenretinide against primary and metastatic intestinal type‑gastric cancer.
Ortiz N, Diaz C Oncol Lett. 2024; 28(6):561.
PMID: 39372665 PMC: 11450695. DOI: 10.3892/ol.2024.14694.
Sekeroglu Z, Sekeroglu V Curr Cancer Drug Targets. 2024; 25(2):118-130.
PMID: 38445692 DOI: 10.2174/0115680096285910240206044830.
Microphysiological systems for human aging research.
Park S, Laskow T, Chen J, Guha P, Dawn B, Kim D Aging Cell. 2024; 23(3):e14070.
PMID: 38180277 PMC: 10928588. DOI: 10.1111/acel.14070.